NCT00186810View on ClinicalTrials.gov

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 1992

Primary Completion Date

February 28, 2006

Study Completion Date

October 31, 2007

Conditions
Sickle Cell Disease
Interventions
DRUG

Busulfan, Cyclophosphamide, Horse ATG

Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.

PROCEDURE

Allogeneic stem cell transplant

Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00186810 - Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter